NCT07506863Phase 3Recruiting

A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)

Study sponsor: Agios Pharmaceuticals, Inc. · AGIO

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2029-06Estimated
Enrollment · participants54Estimated
Source updated2026-10-29Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Not yet recruiting. After: Recruiting.

Check registry source